Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/08/cvbnchfgyjuf6rr5tyrydxfrfes1.png)
Multiple Myeloma Solution ** Breakthroughs and Hope in Blood Cancer Treatment**
Multiple Myeloma Solution
** Breakthroughs and Hope in Blood Cancer Treatment**
![Mutiple Myeloma](https://www.medtourcn.com/wp-content/uploads/2024/08/cvbnchfgyjuf6rr5tyrydxfrfes1.png)
Mutiple Myeloma
Multiple myeloma is a malignant blood cancer caused by the abnormal proliferation of plasma cells in the bone marrow, often affecting the bones, kidneys, and various organs and systems. With the advancement of modern medical technology, the understanding and treatment of multiple myeloma have greatly improved, bringing unprecedented hope to patients.
### Causes and Risk Factors of Multiple Myeloma
The causes of multiple myeloma are complex, typically involving multiple factors such as genetic mutations, immune system abnormalities, exposure to harmful chemicals, viral infections, and genetic predisposition. Additionally, lifestyle and environmental factors like smoking, obesity, and certain occupational exposures are also believed to increase the risk of developing the disease. With an aging population, the incidence of multiple myeloma is on the rise.
### Evolution of Treatment: Traditional and Innovative Approaches
Although multiple myeloma was once considered a difficult-to-treat disease, recent advancements in treatment methods have made significant progress. Traditional treatments include chemotherapy, radiation therapy, and bone marrow transplantation, which have extended patients’ survival to some extent but come with limited efficacy and significant side effects.
However, with advances in medical technology, new treatment options have emerged. Monoclonal antibodies have played a key role in treating multiple myeloma, targeting cancer cells precisely while reducing harm to healthy cells. Antibody-drug conjugates take this a step further by delivering chemotherapy drugs directly to cancer cells, enhancing efficacy while minimizing side effects.
Small molecule targeted drugs represent another breakthrough. These drugs inhibit specific genes or proteins in cancer cells, preventing their growth and spread. For example, BCL-2 inhibitors and protein kinase inhibitors have shown promising results in clinical trials, offering more treatment options.
### Immunotherapy: Leading the Future of Hope
Immunotherapy is becoming increasingly important in the treatment of blood cancers, especially in the field of multiple myeloma. By activating the patient’s own immune system to attack cancer cells, immunotherapy holds great promise. Among the most forward-looking therapies is CAR-T cell therapy. This treatment involves genetically modifying a patient’s T cells to recognize and kill cancer cells, and it has achieved remarkable results in multiple myeloma patients.
In recent years, China has made significant progress in the research and application of immunotherapy. Particularly in the field of blood cancers, China has developed a comprehensive treatment system with established protocols and consensus. The BCMA-targeted CAR-T cell therapy has shown deep and lasting efficacy in treating multiple myeloma, greatly improving patients’ disease-free survival rates. For instance, China’s fully human BCMA-targeted CAR-T product, Equecabtagene Autoleucel, has demonstrated the best data among CAR-T products for multiple myeloma, with a complete remission rate of 82.4%.
### Looking Ahead
With the continuous emergence of new drugs and therapies, the treatment of multiple myeloma is moving towards individualized and precision medicine. Patients not only experience extended lifespans but also regain their quality of life, returning to normalcy in their everyday lives and work. As medical advancements continue, there is reason to believe that multiple myeloma will no longer be an incurable disease, and every patient will be able to embrace a brighter future.
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070 (Http://wa.me/+8613717959070)
Email: doctor.huang@globecancer.com
#BloodCancerTreatment #CAR_TCellTherapy #CancerBreakthrough #Immunotherapy #BCMACART #MedicalAdvancements #CancerSurvivorship #ChinaMedicalInnovation #HopeForCancerPatients
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/08/微信截图_20240801100213.jpg)
Blood Cancer Solution Including leukemia, lymphoma, multiple myeloma, and others.
Blood Cancer Solution![👍](https://static.xx.fbcdn.net/images/emoji.php/v9/tfc/1/16/1f44d.png)
Including leukemia, lymphoma, multiple myeloma, and others.
![Blood Cancer](https://www.medtourcn.com/wp-content/uploads/2024/08/微信截图_20240801100213.jpg)
Blood Cancer
#leukemia #lymphoma #multiplemyeloma
#Hematologic malignancies are a group of malignant diseases originating from hematopoietic cells, often affecting the bone marrow, blood, and various organs and tissues throughout the body. Common types of hematologic malignancies include leukemia, myelodysplastic syndromes, lymphomas, multiple myeloma, and myeloproliferative neoplasms.
The causes of these diseases are complex, involving genetic mutations, immune abnormalities, radiation exposure, contact with harmful chemicals, infections, and hereditary factors. Additionally, poor lifestyle habits, high levels of stress, and environmental factors can also increase the risk of developing these conditions.
With an aging population and advancements in medical technology, the incidence of hematologic malignancies has been rising globally. In China, the incidence and mortality rates of leukemia and lymphoma are now among the top ranks of all malignancies.
However, hematologic malignancies are not incurable. In recent years, the treatment methods for these diseases have seen significant progress. From traditional combination chemotherapy and radiotherapy to hematopoietic stem cell transplantation, monoclonal antibody therapy, antibody-drug conjugates, small molecule targeted therapies, and the latest immunotherapies, treatment options have become increasingly diverse and precise.
Combination chemotherapy remains a primary treatment for many hematologic malignancies, despite its significant side effects. The efficacy of these treatments cannot be ignored. Modern chemotherapy regimens are continually being refined, including the incorporation of new cytotoxic drugs and targeted therapies, as well as the use of monoclonal antibodies. Additionally, the appropriate use of antiemetics, hematopoietic growth factors, and anti-infective agents helps to mitigate adverse effects.
Hematopoietic stem cell transplantation continues to be one of the most effective treatments for certain hematologic malignancies. The development of this treatment in China has been rapid, with 170 registered transplant centers by 2020.
Monoclonal antibodies, often referred to as “biological missiles,” have a high degree of specificity and single biological activity. They have revolutionized the treatment of hematologic malignancies. Antibody-drug conjugates (ADCs) utilize monoclonal antibodies to accurately identify tumor cell markers, guiding the delivery of chemotherapy drugs for targeted treatment.
Small molecule targeted therapies work by interfering with specific genes or proteins to inhibit tumor cell growth and proliferation. Gleevec, the first small molecule targeted therapy, increased the five-year survival rate for chronic myeloid leukemia (CML) patients from 30% to 89%, marking a breakthrough in cancer treatment. Today, there are numerous small molecule targeted drugs available for the treatment of hematologic malignancies, including BCR-ABL inhibitors, BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors, and XPO1 inhibitors, with many more drugs currently in clinical trials expected to become available soon.
Immunotherapy includes immune checkpoint inhibitors (such as PD-1/L1), cancer vaccines, cellular immunotherapies (such as #CART), and nonspecific immunomodulatory treatments. #CARTtherapy, in particular, has gained widespread attention as an emerging curative treatment. This approach involves extracting a patient’s T cells, modifying them outside the body to specifically recognize and attack tumor cells, and then reinfusing the modified T cells into the patient. This therapy has been successfully applied to various hematologic malignancies, including acute lymphoblastic leukemia, lymphomas, and multiple myeloma. The first patient treated with CAR-T therapy has been disease-free for 11 years.
In recent years, China has made significant advances in the treatment of hematologic malignancies. The establishment of the “Chinese Expert Consensus on the Diagnosis and Treatment of High-Risk Multiple Myeloma” and the presentation by Professor Huang He at the 2024 #EHA conference on targeting CD7 universal CAR-T therapy for T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) have shown remarkable efficacy and safety. Additionally, exciting new data from the 2024 American Society of Clinical Oncology (#ASCO) annual meeting highlighted the efficacy of Relma-cel in treating relapsed/refractory large B-cell lymphoma (R/R LBCL), with a four-year overall survival rate (#OS) of 66.7%. Particularly noteworthy is the research on multiple myeloma, where the BCMA-targeted CAR-T therapy has demonstrated deep and lasting responses, with a complete response (#CR) rate of 82.4% and a 12-month progression-free survival (#PFS) rate of 85.5%.
With the continuous development of new treatments and the emergence of new drugs, hematologic malignancies in China are no longer considered incurable diseases. Through standardized, individualized, and precise treatments, many patients with hematologic malignancies can achieve long-term disease-free survival, and even a cure, returning to normal work and life. As medicine continues to advance, every life will continue to shine brightly!
![🎉](https://static.xx.fbcdn.net/images/emoji.php/v9/t8c/1/16/1f389.png)
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com![👍](https://static.xx.fbcdn.net/images/emoji.php/v9/tfc/1/16/1f44d.png)
#HematologicMalignancies #LeukemiaAwareness #LymphomaResearch #MultipleMyeloma #BloodCancer #CancerResearch #CAR_Therapy #StemCellTransplant #Immunotherapy #TargetedTherapy #MonoclonalAntibodies #CancerTreatment #MedicalAdvancements #CancerSurvivor #HealthcareInnovation
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/07/微信截图_20240712114012.jpg)
**2024 EHA | Breaking Through Multiple Myeloma Treatment Bottlenecks: Significant Advances of Equecabtagene Autoleucel in High-Risk NDMM Patients**
**2024 EHA | Breaking Through Multiple Myeloma Treatment Bottlenecks: Significant Advances of Equecabtagene Autoleucel in High-Risk NDMM Patients**
![Multiple Myeloma](https://www.medtourcn.com/wp-content/uploads/2024/07/微信截图_20240712114012.jpg)
Multiple Myeloma
Multiple Myeloma (MM) is a malignant plasma cell disorder and one of the most common hematologic malignancies. In China, approximately 20,000 new cases of newly diagnosed multiple myeloma (NDMM) are reported annually, with a median age at diagnosis over 60 years. It is reported that Chinese MM patients generally exhibit higher rates of cytogenetic abnormalities, with an incidence rate exceeding 40%, which is significantly higher than in Western countries.
High-risk MM patients often respond poorly to existing treatment regimens and face limited treatment options. Many elderly patients are frail and have multiple comorbidities, making them less tolerant of the adverse reactions associated with current therapies, particularly autologous stem cell transplantation (ASCT). Once the disease progresses to a refractory/relapsed state, the combination of advanced age, frailty, and high-risk cytogenetic abnormalities leads to limited salvage treatment options, worsening efficacy, and poor prognosis. Thus, selecting effective frontline therapy for NDMM patients, especially high-risk elderly patients unsuitable for transplantation, is a pressing clinical need, requiring innovative therapies to supplement existing treatments. The new generation of cell immunotherapies, exemplified by Equecabtagene Autoleucel, holds promise to fill this gap and potentially become a breakthrough for high-risk NDMM.
In the FUMANBA-1 study, which included 69.5% high-risk patients, Equecabtagene Autoleucel achieved an ORR of 96.1% and has been approved in China for treating third-line or later relapsed/refractory multiple myeloma (R/R MM) patients. This EHA meeting is the first to present oral data on the efficacy and safety of Equecabtagene Autoleucel in the FUMANBA-2 study for high-risk, newly diagnosed, transplant-ineligible MM patients.
### Study Introduction
FUMANBA-2 is a multicenter, open-label, single-arm Phase I study designed to evaluate the efficacy and safety of Equecabtagene Autoleucel in transplant-ineligible NDMM patients with 100% high-risk features (defined by mSMART 3.0: RISS Stage III, double-hit, or triple-hit). Patients received four cycles of induction therapy, including the VRd regimen (Bortezomib, Lenalidomide, Dexamethasone), the VCD regimen (Bortezomib, Cyclophosphamide, Dexamethasone), or the PAD regimen (Bortezomib, Doxorubicin, Dexamethasone). After the third cycle of induction therapy, T cells were collected from patients unsuitable for ASCT and Equecabtagene Autoleucel was prepared. After lymphodepletion, patients received a single infusion of Equecabtagene Autoleucel at a dose of 1.0 x 10^6 CAR-T cells/kg. The primary efficacy endpoints were the proportion of MRD-negative patients and progression-free survival (PFS). Secondary endpoints included objective response rate, duration of response, safety, pharmacokinetics, and pharmacodynamics.
### Study Results
As of January 25, 2024, 16 patients received Equecabtagene Autoleucel, with a median age of 58.5 years (51-69) and a median follow-up time of 13.1 months (7.9-24.3). All patients had high-risk cytogenetics, with 62.5% (10/16) being double-hit, 12.5% (2/16) being triple-hit, and 25% (4/16) having extramedullary disease. 37.5% (6/16) were R-ISS Stage III, with one patient each combining R-ISS Stage III with double-hit and triple-hit characteristics.
The median follow-up time after Equecabtagene Autoleucel infusion was 7.46 months (2.8-18.1). The median PFS was not reached, with a 12-month PFS rate of 84.4% (95% CI: 49.31-96.00). All subjects achieved MRD negativity, with 71.4% (95% CI: 25.8-92.0) maintaining MRD negativity for over 12 months. The objective response rate (ORR) was 100%, with 93.8% (15/16) achieving stringent complete response (sCR).
Grade 1-2 cytokine release syndrome (CRS) occurred in 68.8% (11/16) of patients, with no grade 3 or higher CRS, immune effector cell-associated neurotoxicity syndrome (ICANS), or neurotoxicity. The most common grade 3 or higher drug-related adverse events were hematologic, with a 25.0% (4/16) incidence of grade 3 or higher infectious disease adverse events.
The median peak CAR copy number in peripheral blood was reached on day 10 (7-21) post-infusion, with a median peak level of 79,681.299 copies/μg gDNA. 81.25% (13/16) of patients achieved free B cell maturation antigen (sBCMA) clearance within one month post-infusion. Median peak levels of inflammatory cytokines IL-6, CRP, and ferritin were 64.28 pg/mL (9.12-3017.83), 49.30 mg/L (3.66-117.30), and 553.35 ng/mL (68.10-2349.00), respectively. The median peak times for IL-6 and CRP were day 7 and day 10, respectively, with no significant change in serum ferritin levels compared to pre-infusion.
### Study Outlook
The FUMANBA-2 study of Equecabtagene Autoleucel demonstrates the efficacy and safety of a novel fully human BCMA CAR-T therapy in high-risk, transplant-ineligible, newly diagnosed multiple myeloma patients. This is the first international report of CAR-T therapy as frontline treatment in this specific population. The study highlights the potential application of cell immunotherapy in the MM field. Compared to traditional chemotherapy and new drug treatments, frontline CAR-T therapy for NDMM has the potential to further improve response rates, extend survival, and improve prognosis, particularly for high-risk cytogenetic abnormalities and high tumor burden. For elderly and frail patients who are unsuitable for hematopoietic stem cell transplantation, CAR-T therapy may fill the treatment gap to some extent. The one-time treatment approach, as opposed to continuous chemotherapy or multiple transplants, offers patients better quality of life and treatment convenience. Although CAR-T therapy carries risks such as CRS and neurotoxicity, these side effects are manageable in many studies, and safety improves with treatment experience and management strategies. Bringing CAR-T therapy to the frontline provides patients with more diverse and promising treatment options. However, large-scale, long-term follow-up studies are needed to validate its long-term efficacy and survival benefits, and further exploration and optimization are required for the best administration timing, regimen, and duration.
In summary, the FUMANBA-2 study of Equecabtagene Autoleucel shows significant treatment potential in newly diagnosed, transplant-ineligible multiple myeloma patients. With accumulating research evidence and advances in CAR-T technology, we anticipate CAR-T therapy will benefit more patients in the future.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#EquecabtageneAutoleucel #MultipleMyeloma #MMTreatment #HighRiskMM #NDMM #CAR_Therapy #Immunotherapy #BloodCancer #OncologyResearch #EHA2024 #CancerBreakthrough #CellTherapy #MyelomaTreatment #ClinicalTrials #InnovativeMedicine #HealthcareAdvancements
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/06/微信截图_20240627163822.jpg)
**2024 ASCO: National Institute’s New CAR-T Therapy CD7 CAR-T Cells, Multiple Blood Cancer Destroyers**
**2024 ASCO: National Institute’s New CAR-T Therapy CD7 CAR-T Cells, Multiple Blood Cancer Destroyers**
![CAR-T Therapy](https://www.medtourcn.com/wp-content/uploads/2024/06/微信截图_20240627163822.jpg)
CAR-T Therapy
**2024 ASCO: Four Chinese-developed CAR-T therapies make a significant impact, targeting colorectal cancer, pancreatic cancer, and hematological tumors, with an overall response rate nearing 100.0%**
**CD7 CAR-T Cells: A Powerful Strike Against Hematological Tumors, Patients Achieve Complete Remission**
Patients with relapsed or refractory hematologic malignancies have limited treatment options and poor prognosis, with a 5-year overall survival rate of less than 20%. While allogeneic hematopoietic stem cell transplantation (HSCT) provides a critical strategy for treating aggressive hematologic cancers, HSCT treatment can also result in adverse reactions such as graft-versus-host disease (GVHD) and conditioning-related toxicities. Additionally, some patients with poor health cannot undergo this treatment. Therefore, new treatment methods are urgently needed, and the emergence of CAR-T therapy has brought new hope to patients with hematologic tumors.
The world-renowned journal, *The New England Journal of Medicine*, reported on a clinical study of “CD7 CAR-T cells for the treatment of relapsed or refractory CD7-positive hematologic tumors” (NCT04599556).
From November 2021 to September 2023, 10 patients with relapsed or refractory CD7-positive cancers were enrolled in the study, including 7 cases of acute myeloid leukemia (AML), 2 cases of T-cell acute lymphoblastic leukemia (ALL), and 1 case of T-cell lymphoblastic lymphoma (IVA stage). The median age was 56.5 years (range, 13.7–72.5 years). All patients had bone marrow involvement, with a median blast cell percentage of 36.0% (range, 2–87), and a median CD7 expression on blast cells of 93.0% (range, 80.7–97.7). All patients had received extensive prior treatments, with a median of 9.5 courses (range, 4–15 courses). After enrollment, patients first received an intensive lymphocyte-depleting regimen (cyclophosphamide, fludarabine, etoposide) and then CD7 CAR-T cell infusion therapy. After a median follow-up of 15.1 months, the results showed:
-
**Complete Remission (CR):** All patients (n=10) achieved complete remission (CR) after CAR-T cell therapy, though hematologic recovery was incomplete, with grade 4 pancytopenia. As of November 8, 2023 (data cutoff date), 6 patients had not received any further treatment and remained in minimal residual disease (MRD) negative complete remission.
-
**Overall Survival Rate:** The estimated 1-year overall survival rate was 68% [95% Confidence Interval (CI), 43–100].
-
**Disease-Free Survival Rate:** The estimated 1-year disease-free survival rate was 54% (95% CI, 29–100).
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#ASCO2024 #CARTherapy #BloodCancer #CD7CART #CancerResearch #Hematology #MedicalInnovation #CART
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/06/图片1.png)
Breakthrough Therapy Brings New Hope: Swiss Patient Thomas Begins CAR-T Treatment at Tongji Hospital, Wuhan
**Breakthrough Therapy Brings New Hope: Swiss Patient Thomas Begins CAR-T Treatment at Tongji Hospital, Wuhan**
Professor Li Chunrui’s team at Tongji Hospital in Wuhan successfully conducted a case of chimeric antigen receptor T-cell (CAR-T) immunotherapy for a patient with relapsed and refractory multiple myeloma, offering new life to Swiss patient Thomas.
Thomas, a 54-year-old patient from Switzerland, has been battling multiple myeloma for nearly ten years. Initially diagnosed in 2016, he has endured severe bone pain and undergone multiple rounds of systemic chemotherapy and monoclonal antibody therapy. Although his condition was temporarily controlled, repeated relapses, with the most recent in 2022, made treatment increasingly challenging.
However, the global development of CAR-T therapy has reignited hope. The introduction of FUCASO (Eque-cel), the first fully human CAR-T product in mainland China, has brought new light to Thomas. This groundbreaking treatment not only boasts low immunogenicity but also offers prolonged efficacy, enabling patients to return to a high quality of life.
Thomas ultimately chose to receive the cutting-edge CAR-T therapy at Tongji Hospital, seeking a fundamental breakthrough in his treatment. The apheresis procedure was conducted by the hospital’s top hematology team, who possess international-level expertise and place special emphasis on patient-specific needs and treatment safety. The attending physician elaborated on the apheresis process in an interview, saying, “We precisely collected T-cells from Thomas’s body, then modified these cells in a controlled environment to specifically target multiple myeloma cancer cells. The use of FUCASO greatly enhanced the treatment’s specificity and success rate.”
Thomas expressed high recognition and appreciation for the hospital team’s professionalism and the transparency of the treatment process. Tongji Hospital leveraged its advanced technology and equipment to provide Thomas with a smooth and efficient apheresis experience, ensuring high-quality T-cell collection and paving the way for the subsequent treatment.
Thomas is now filled with confidence and anticipation, looking forward to the new life that CAR-T therapy promises. This new beginning marks a significant step in his treatment journey, injecting new hope into his path to recovery.
We will continue to follow up on the patient’s subsequent treatment and report on the progress.
CART MultipleMyeloma FUCASOJourney Equecel TongjiHospital CancerSurvivor BloodCancer Immunotherapy FullyHumanCART CancerTreatment
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/06/微信截图_20240613110236.jpg)
Interpretation of Hot Topics Conerning Relapsed/Refractory Mutiple Myeloma Patients
Interpretation of Hot Topics Conerning Relapsed/Refractory Mutiple Myeloma Patients:![💐](https://static.xx.fbcdn.net/images/emoji.php/v9/te3/1/16/1f490.png)
What other treatment options are available for patients with relapsed Multiple Myeloma?
How effective is the new drug treatment for the first relapse of Multiple Myeloma?
What treatment options are available for initial relapse of multiple myeloma?
What are the treatment goals for Relapsed/Refractory Multiple Myeloma (RRMM)?
What treatment strategy should be adopted for RRMM in order to achieve maximum relief?
For Relapsed/Refractory Multiple Myeloma, what are the Grades of Response?
Expert Introduction
👩🔬Zhuang Junling
Associate Chief Physician Department of Hematology
Peking Union Medical College Hospital
Published over 50 papers in journals such as Blood, Leukemia Research, and others.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#CART #Mutiplemyeloma #CARTtherapy #myeloma #leukemia #drug #RRMM #cancer #cancersurvivor #cancerpatient #bloodcancer #tumor #cartcell #cartcelltherapy #cancertreatment #advancedmedicineinchina #hematology
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/06/回输视频-英语封面-封面.jpg)
Key Steps in Precision Treatment: A Detailed Overview of CAR-T Infusion for a Russian Patient at Jiahui in Shanghai
Key Steps in Precision Treatment: A Detailed Overview of CAR-T Infusion for a Russian Patient at Jiahui in Shanghai**
Vladimir Borzenkov, a 68-year-old patient from St. Petersburg, Russia, recently completed the core phase of CAR-T therapy—reinfusion—at Jiahui International Hospital in Shanghai. This crucial step involves reinfusing T-cells, which have been genetically modified to recognize and attack specific cancer cells, back into the patient’s body. For Mr. Vladimir, who has been battling his condition for over five years, this step is particularly significant.
Before the reinfusion, the medical team conducted a comprehensive physical assessment to ensure his body could withstand the procedure. Despite being in his sixties, Vladimir’s determination and desire for a cure helped him overcome any obstacles posed by his age. His journey began in December 2017 with back pain, which progressively worsened over several months. By February 2018, multiple bones, including his spine, sternum, and clavicle, showed signs of deterioration. Although this period seemed like a relentless trial, Vladimir never lost his faith in life. Now, at this critical juncture, he is filled with hope for the future.
For this treatment, Jiahui Hospital utilized FUCASO (Eque-cel), a fully human CAR-T therapy known for its unique low immunogenicity and lasting efficacy, providing therapeutic advantages for the patient. During the reinfusion process, Jiahui Hospital demonstrated advanced capabilities in monitoring and managing adverse reactions. The hospital is equipped with the latest monitoring technology and a highly experienced medical team, ensuring that any potential adverse reactions are promptly identified and managed, thus ensuring the safety and effectiveness of the treatment. This high level of monitoring and detailed attention to the patient’s health made Vladimir’s treatment process not only efficient but also safe.
Through his experience at Jiahui International Hospital, Vladimir witnessed the powerful potential of CAR-T therapy and the significant advantages of FUCASO. He is now filled with hope for the future treatment outcomes. This treatment marks not only a significant milestone in his personal battle against cancer but also showcases Jiahui’s expertise in CAR-T technology and excellent patient care.
#CART #MultipleMyeloma #FUCASOJourney #Equecel #JiahuiHospital #Shanghai #CancerSurvivor #bloodcancer #Immunotherapy #FullyHumanCART #CancerTreatment
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/05/俄语封面.jpg)
Ключевой этап точечного лечения: Подробное объяснение афереза CAR-T для российского пациента в Шанхайской Международной больнице Жияхуи
Ключевой этап точечного лечения:
Подробное объяснение афереза CAR-T для российского пациента в Шанхайской Международной больнице Жияхуи
Владимир Борзенков, 68-летний пациент из Санкт-Петербурга, в последнее время прошел важный этап лечения CAR-T в Международной больнице Жияхуи в Шанхае – аферез. Этот процесс включает в себя сбор Т-клеток из организма пациента для дальнейшей генетической модификации и увеличения. Владимир выразил благодарность профессионализму лечебной команды и прозрачности лечебного процесса, что не только сняло его беспокойство, но и увеличило уверенность в успехе лечения. Больница Жияхуи использовала свои передовые устройства и технологии, чтобы обеспечить Владимиру плавный и эффективный опыт афереза, гарантируя высококачественный сбор Т-клеток и заложив прочный фундамент для следующих этапов лечения.
#CART #МножественнаяМиелома #ОдобрениеФУКАСО #Эквесел #БольницаЖияхуи #Шанхай #ВыжившийОтРака #КровяноеРак #Иммунотерапия #ПолностьюЧеловеческийCART
#CART #MultipleMyeloma #FUCASOapproval #Equecel #JiahuiHospital #Shanghai #CancerSurvivor #bloodcancer #Immunotherapy #FullyHumanCART
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/05/微信截图_20240524143613.jpg)
Key Step in Precision Treatment: Detailed Explanation of CAR-T Apheresis for a Russian Patient at Jiahui International Hospital in Shanghai
Title:
Key Step in Precision Treatment: Detailed Explanation of CAR-T Apheresis for a Russian Patient at Jiahui International Hospital in Shanghai
Content:
Vladimir Borzenkov, a 68-year-old Russian patient from Saint Petersburg, recently underwent a crucial step in CAR-T therapy at Jiahui International Hospital in Shanghai – apheresis. This process involves collecting T cells from the patient’s body for further genetic modification and amplification. Vladimir expressed appreciation for the professionalism of the treatment team and the transparency of the treatment process, which not only alleviated his anxiety but also increased confidence in the success of the treatment. Jiahui Hospital utilized its advanced facilities and technology to provide Vladimir with a smooth and efficient apheresis experience, ensuring high-quality collection of T cells and laying a solid foundation for the next steps of treatment.
#CART #MultipleMyeloma #FUCASOapproval #Equecel #JiahuiHospital #Shanghai #CancerSurvivor #bloodcancer #Immunotherapy #FullyHumanCART
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/03/202403240000.png)
🍀Miraculous Journey Across Borders: Mr. Barankov’s Triumph with CAR-T Therapy in China 🍀
🍀Miraculous Journey Across Borders: Mr. Barankov’s Triumph with CAR-T Therapy in China 🍀
![Hope of patients](https://www.medtourcn.com/wp-content/uploads/2024/03/202403240000.png)
Hope of patients
🌱Meet Mr. Barankov
a 68-year-old patient from Saint Petersburg, Russia, who was unexpectedly diagnosed with multiple myeloma in 2018. After four years of international consultations, he discovered that China has made significant advancements in CAR-T therapy compared to European medical institutions in Spain, Munich, Heidelberg, and others.
🌿The treatment outcomes in China are leading globally.
Following unsuccessful traditional chemotherapy and two autologous hematopoietic stem cell transplants, he had the opportunity for an online consultation with experts from Jiahui International Hospital in Shanghai. During the virtual consultation, Mr. Barankov was impressed by the expertise of the Chinese medical team and the therapeutic potential of the fully human CAR-T drug FUCASO (Eque-cel). Considering China’s leading position in CAR-T therapy, more competitive costs, and relatively shorter wait times, Mr. Barankov made a significant decision to travel to China for treatment.
☘️#MiracleJourney #CARTTherapy #CrossingBorders #CART #Hopeofpatients #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/03/上海同济泰国患者单采3-封面.jpg)
ความหวังใหม่สำหรับผู้ป่วยโรคมีเลือดมาก (Multiple Myeloma) – เริ่มต้นการรักษาด้วย CAR-T Therapy
🎯ความหวังใหม่สำหรับผู้ป่วยโรคมีเลือดมาก (Multiple Myeloma) – เริ่มต้นการรักษาด้วย CAR-T Therapy🎯
⭐เมื่อเร็ว ๆ นี้ ทีมของศาสตราจารย์ ดร. ลิ ปิง ณ โรงพยาบาลตงจิ ในเซี่ยงไฮ้ ได้ดำเนินการรักษาด้วยการภูมิคุ้มกันเซลล์ T ที่มีภูมิลักษณ์ผสม (Chimeric Antigen Receptor T-Cell Immunotherapy หรือ CAR-T) สำเร็จสำหรับผู้ป่วยโรคมีเลือดมากที่ซ้ำกลับและซ้ำแล้วและซ้ำไม่ได้ (R/RMM) นี่เป็นการรักษาที่เปิดโอกาสใหม่สำหรับการรักษาผู้ป่วย R/RMM
🌟ผู้ป่วยที่ได้รับการรักษาด้วย CAR-T นี้ได้รับการวินิจฉัยว่าเป็นโรคมีเลือดมากในเดือนกรกฎาคม พ.ศ. 2564 ในประเทศไทย โรคมีเลือดมากของผู้ป่วยมีภาระรักษามาก โรครุนแรง แม้จะได้รับการรักษาด้วยเคมีบำบัดระบบทั่วไป โมโนคลอนอนิบอดี้ การปลูกถ่ายเซลล์ลำไส้โภชนาการของตนเอง (ASCT) และการรักษาอื่น ๆ โรคยังกลับมาซ้ำกลับหลายครั้ง ในระยะเวลาของโรคเพียง 2 ปี เข้าสู่การรักษาหลายเส้นทาง และเจริญสามารถรับการรักษาอย่างเป็นตัวอย่าง ไม่สามารถควบคุมโรคได้อย่างมีประสิทธิภาพ
🌠 เมื่อจำนวนการเกิดการซ้ำกลับเพิ่มขึ้นในผู้ป่วย R/RMM และจำนวนของเส้นทางการรักษาขยายออก การตอบสนองต่อการรักษาก็เลวร้ายลงและระยะเวลาของการหายตัวยังกลับมาสั้นลง อย่างไรก็ตาม ด้วยการอนุมัติยา CAR-T therapy ที่เป็นมนุษย์ที่สมบูรณ์แบบแรกในโลก ชื่อ FUCASO (Eque-cel) ในจีนใหญ่ ความหวังใหม่ก็ได้ถูกเปิดขึ้นอย่างไม่สงบสำหรับการรักษาโรคมีเลือดมาก โครงสร้าง CAR ที่เป็นมนุษย์ที่สมบูรณ์แบบของมันไม่เพียงแต่มีความต้านทานต่อร่างกายน้อย แต่ยังมีการปลดตัวออกและการใช้งานต่ำ ทำให้ผู้ป่วยสามารถกลับไปสู่ระดับคุณภาพชีวิตที่สูงขึ้นด้วยการรักษาแค่ครั้งเดียว
☄หลังจากทีมของศาสตราจารย์ ดร. ลิ ปิง ประเมินพิจารณาพบว่าผู้ป่วยมีเงื่อนไขที่เหมาะสมสำหรับการรักษาด้วยเซลล์ CAR-T หลังจากการสื่อสารอย่างเต็มที่ระหว่างแพทย์กับผู้ป่วยและครอบครัวของเขา ผู้ป่วยในที่สุดก็เลือกที่จะรับการรักษาด้วย CAR-T และได้ทำการรวบรวมเซลล์โมโนเนวกลุ่มเลือดเป็นรายในเดือนพฤศจิกายน พ.ศ. 2566
✨ เราจะติดตามความคืบหน้าของการรักษาของผู้ป่วยต่อไปและรายงานติดตามต่อไป
#CARTTreatment #CARTTherapy #HopeReborn #FUCASOApproval #EquecelApproval #MultipleMyeloma #TongjiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART
หมายเหตุ: ภาพถ่ายและข้อมูลได้รับอนุญาตจากโรงพยาบาล ผู้ป่วย และครอบครัวของผู้ป่วย
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/02/202402270.png)
A New Chapter in Survival! A Quadruple Drug Combination Opens Up a New Treatment Pathway for Multiple Myeloma Patients
🌟 *A New Chapter in Survival! A Quadruple Drug Combination Opens Up a New Treatment Pathway for Multiple Myeloma Patients.* 🌟
![NEJM, Multiple myeloma](https://www.medtourcn.com/wp-content/uploads/2024/02/202402270.png)
#NEJM, #Multiple myeloma